6 completed, 2 recruiting, 1 not yet recruiting, 1 unknown. 6 Phase 2, 4 Phase 3, 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 3, Recruiting 2, Unknown 1 |
| Phase 3 | 4 | Completed 2, Not yet recruiting 1, Recruiting 1 |
| Not applicable | 1 | Completed 1 |
| Phase 1 | 1 | Completed 1 |
Follow Cyclosporine A (CsA): new trials by email Literature Review of Cyclosporine A (CsA) trials Research Report on Cyclosporine A (CsA)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Osimertinib and Cyclosporine A to Enhance Antitumor Efficacy in NSCLC Osimertinib, Cyclosporine A (CsA), ctDNA Biopsy Panel - Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor | Phase 2 | Recruiting | NYU Langone Health | 60 | 2026-10-01 | 2026-10-15 |
| A Study of Romiplostim N01 Plus IST vs. Placebo Plus IST for Treatment-Naive Severe Aplastic Anemia Romiplostim N01, Cyclosporine A (CsA), pALG/ rATG - Treatment-naïve Severe Aplastic Anemia | Phase 3 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 210 | 2026-01-01 | 2026-01-15 |
| Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies Cyclosporine A (CsA), Sirolimus, Ruxolitinib (JAKAVI®) - Acute Myeloid Leukemia, Relapsed, Acute Lymphoblastic Leukemia, High Risk | Phase 2 / Phase 3 | Recruiting | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 64 | 2025-09-03 | 2026-01-26 |
| Combination of Eltrombopag With Immunosuppressive Therapy in East-Asian Patients With Severe Aplastic Anemia eltrombopag, rabbit anti-thymocyte globulin (r-ATG), cyclosporine A (CsA) - Severe Aplastic Anemia (SAA) | Phase 2 | Completed | Novartis Pharmaceuticals | 36 | 2020-11-04 | 2026-01-13 |
| Safety and Efficacy Study of Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells to Treat Myelodysplastic Syndromes Human umbilical cord-derived MSCs, cyclosporine A (CsA) - Myelodysplastic Syndromes | Phase 2 | Unknown | Shandong University | 30 | 2010-05-01 | 2010-05-25 |
| Immune Tolerance Study With Aldurazyme® (Laronidase) Laronidase, Cyclosporine A (CsA), Azathioprine (Aza) - Mucopolysaccharidosis I | Phase 1 / Phase 2 | Completed | Genzyme, a Sanofi Company | 7 | 2008-09-01 | 2014-07-02 |
| A Study of CellCept (Mycophenolate Mofetil) in Combination Therapy in Heart Transplant Patients. mycophenolate mofetil (MMF), cyclosporine A (CsA), corticosteroids - Heart Transplantation | Phase 3 | Completed | Hoffmann-La Roche | 36 | 2006-08-01 | 2014-10-29 |
| Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients Everolimus, Mycophenolic Acid (MPA), Cyclosporine A (CsA) - Kidney Transplantation, Graft Rejection | Phase 3 | Completed | Novartis | 833 | 2005-10-01 | 2011-05-10 |
| Photophoresis Versus Ciclosporine in Severe Atopic Dermatitis Cyclosporine A (CsA), Extracorporeal photopheresis (ECP) - Atopic Dermatitis | Not applicable | Completed | University of Aarhus | 20 | 2002-06-01 | 2015-03-27 |
| Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant Pentostatin, Total-body irradiation (TBI), Cyclosporine A (CsA) - Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia | Phase 2 | Completed | University of Nebraska | 76 | 2000-12-08 | 2023-10-24 |
Leukemia, Myeloid, Acute (2) · Myelodysplastic Syndromes (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Anemia, Aplastic (1) · Bone Marrow Diseases (1) · Carcinoma, Non-Small-Cell Lung (1) · Dermatitis, Atopic (1) · Hodgkin Disease (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Lymphoma, Non-Hodgkin (1) · Lymphoma, T-Cell, Peripheral (1) · Mucopolysaccharidoses (1) · Mucopolysaccharidosis I (1) · Multiple Myeloma (1)
Federal Research Institute of Pediatric Hematology, Oncology and Immunology (1) · Genzyme, a Sanofi Company (1) · Hoffmann-La Roche (1) · NYU Langone Health (1) · Novartis (1) · Novartis Pharmaceuticals (1) · Qilu Pharmaceutical Co., Ltd. (1) · Shandong University (1) · University of Aarhus (1) · University of Nebraska (1)
China (3) · United States (3) · Russia (2) · Brazil (1) · Japan (1) · South Korea (1) · Taiwan (1)
Elaine Shum, MD (1) · Erik Obitz, MD, DMSc (1) · Gregory Bociek, MD (1)